21 May 2024: Original Paper
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014–2020 Korean Organ Transplantation Registry Data Analysis
Hoonsung Park 12CDEF , Hanyoung Lee 3CDF , Seungmin Baik 4DF , Myoung Soo Kim 5ABG , Jaeseok Yang 6ABG , Jong Cheol Jeong 7ABG , Tai Yeon Koo 8ABG , Deok-Gie Kim 9ABG , Jae-Myeong Lee 3ACDFG*DOI: 10.12659/AOT.943588
Ann Transplant 2024; 29:e943588
Table 2 Recipient characteristics.
| HBV(+) graft recipients (n=24) | HCV(+) graft recipient (n=1) | HBV(−)/HCV(−) graft recipients (n=1010) | p value | |
|---|---|---|---|---|
| 57.3±8.8 | 53 | 49.8±13.7 | HBV(+)−HBV(−)/HCV(−): p=0.01 | |
| HBV(+)−HBV(−)/HCV(−): p=0.81 | ||||
| Male | 17 (71%) | 1 (100%) | 993 (98.3%) | |
| Female | 7 (29%) | 0 | 347 (1.7%) | |
| HBV(+)−HBV(−)/HCV(−): p=1 | ||||
| Iso | 24 (100%) | 1 (100%) | 1,010 (100%) | |
| Compatible | 0 | 0 | 0 | |
| HBV(+)−HBV(−)/HCV(−): p=0.40 | ||||
| HCV(+) | 1 (4.2%)a) | 1 (100%) | 66 (6.5%) | |
| HCV(−) | 23 (95.8%) | 0 | 944 (93.5%) | |
| HBV(+)−HBV(−)/HCV(−): p | ||||
| HBV(+) | 24 (100%) | 1 (100%) | 313 (31%) | |
| HBV(−) | 0 | 0 | 697 (69%) | |
| HBV(+)−HBV(−)/HCV(−): p | ||||
| Hepatitis A | 0 | 0 | 10 (1%) | |
| Hepatitis B | 22 (91.6%) | 1 (100%)b) | 323 (31.9%) | |
| Hepatitis C | 0 | 0 | 56 (5.5%) | |
| Hepatitis D | 0 | 0 | 0 | |
| Alcoholic liver disease | 1 (4.2%) | 0 | 421 (41.6%) | |
| Cryptogenic | 0 | 0 | 45 (4.5%) | |
| Autoimmune | 0 | 0 | 26 (2.6%) | |
| Primary biliary cirrhosis | 0 | 0 | 8 (0.8%) | |
| Biliary atresia | 0 | 0 | 30 (3%) | |
| Primary sclerosing cholangitis | 0 | 0 | 3 (0.3%) | |
| Secondary sclerosing cholangitis | 0 | 0 | 3 (0.3%) | |
| Drug reaction | 0 | 0 | 33 (3.3%) | |
| Other cholestatic liver disease | 0 | 0 | 5 (0.5%) | |
| Alagilles syndrome | 0 | 0 | 4 (0.4%) | |
| Glycogen storage disease | 0 | 0 | 1 (0.1%) | |
| Budd-Chiari syndrome | 0 | 0 | 2 (0.2%) | |
| GVH/chronic rejection | 0 | 0 | 7 (0.7%) | |
| Hepatic failure (re-LT) | 1 (4.2%) | 0 | 4 (0.4%) | |
| Others | 0 | 0 | 29 (2.9%) | |
| 22.4±9.3 | 16 | 33.0±15.4 | HBV(+)−HBV(−)/HCV(−): p | |
| 27.8±7.8 | 11 | 35.5±7.1 | HBV(+)−HBV(−)/HCV(−): p | |
| 4.6±3.6 | 4 | 4.5±4.3 | HBV(+)−HBV(−)/HCV(−): p=0.84 | |
| 34.0±11.3 | 30 | 35.8±13.9 | HBV(+)−HBV(−)/HCV(−): p=0.58 | |
| No viable tumor | 5 (20.8%) | 0 (0%) | 126 (12.5%) | HBV(+)−HBV(−)/HCV(−): p=0.21 |
| Within Milan criteria | 1 (25%) | 1 (100%) | 59 (33%) | HBV(+)−HBV(−)/HCV(−): p=1 |
| Beyond Milan criteria | 3 (75%)c) | 0 | 108 (60.3%) | |
| Incidental liver cancer | 0 | 0 | 12 (6.7%) | |
| GVH – graft versus host; MELD – Model for End-stage Liver Disease; KONOS – Korean Network for Organ Sharing; HCC – hepatocellular carcinoma. a) b) c) | ||||